“This study provides valuable insights into how physicians are utilizing JELMYTO in the real-world and reinforces the genuine clinical value of this therapy for patients with LG-UTUC,” said Mark Schoenberg, M.D., Chief Medical Officer, UroGen. “We look forward to additional analyses from this retrospective study as well as prospective and retrospective data from the uTRACT Patient Registry.”